Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease

Stock Information for Provention Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Provention Bio Inc.

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Provention Bio Announces Senior Leadership Addition
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Provention Bio Announces the Grant of Inducement Awards
Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
Provention Bio Announces the Grant of Inducement Awards
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.